Announcements Trials
Browse Landscape

Phase

Phase 2/3 1

Status

Terminated 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 12Gastrointestinal 4Gynecologic 2NET 1Genitourinary 1Endocrine 1Dermatologic 1Breast 1

Conditions

Neuroendocrine Tumors 3Vipoma 1Somatostatinoma 1Neoplasms 1Lung Neoplasms 1Insulinoma 1Glucagonoma 1Gastro-enteropancreatic neuroendocrine tumor 1Gastrinoma 1Carcinoma, Islet Cell 1Adenoma, Islet Cell 1

Interventions

Paclitaxel 2Carboplatin 2taxane 1romidepsin 1repotrectinib 1pralsetinib 1liposomal doxorubicin 1atezolizumab 1Vinorelbine 1Temozolomide 1RRx-001 1Quality of Life 1Pemetrexed 1Patient Reported Outcome Measures 1Oxaliplatin 1Nivolumab 1Molecular Diagnostic Techniques 1Magnetic Resonance Spectroscopy 1Leucovorin 1Lactones 1Irinotecan 1Immunotherapy 1Gemcitabine 1Fluorouracil 1Fluorodeoxyglucose F18 1FAPI-46 1Everolimus 1Etoposide 1Drug Therapy 1Depsipeptides 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Lung Neoplasms × Oxaliplatin × NET × Clear all
NCT00227617 2023-05-22

Combination Chemotherapy and Bevacizumab in Treating Patients With Advanced Neuroendocrine Tumors

University of California, San Francisco

Phase 2/3 Terminated
36 enrolled 14 charts
EndocrineNETThoracic

Vipoma, Glucagonoma, Insulinoma, Adenoma, Islet Cell, Lung Neoplasms, Neoplasms, Somatostatinoma, Gastrinoma, Carcinoma, Islet Cell, Neuroendocrine Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡